139 related articles for article (PubMed ID: 37722926)
1. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
Flohr C; Rosala-Hallas A; Jones AP; Beattie P; Baron S; Browne F; Brown SJ; Gach JE; Greenblatt D; Hearn R; Hilger E; Esdaile B; Cork MJ; Howard E; Lovgren ML; August S; Ashoor F; Williamson PR; McPherson T; O'Kane D; Ravenscroft J; Shaw L; Sinha MD; Spowart C; Taams LS; Thomas BR; Wan M; Sach TH; Irvine AD;
Br J Dermatol; 2023 Nov; 189(6):674-684. PubMed ID: 37722926
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT).
Irvine AD; Jones AP; Beattie P; Baron S; Browne F; Ashoor F; O'Neill L; Rosala-Hallas A; Sach T; Spowart C; Taams L; Walker C; Wan M; Webb N; Williamson P; Flohr C;
Br J Dermatol; 2018 Dec; 179(6):1297-1306. PubMed ID: 29727479
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
Zheng Y; Ding RL; Bu J
Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
7. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.
Chan S; Cornelius V; Cro S; Harper JI; Lack G
JAMA Pediatr; 2020 Jan; 174(1):29-37. PubMed ID: 31764962
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial.
Goujon C; Viguier M; Staumont-Sallé D; Bernier C; Guillet G; Lahfa M; Ferrier Le Bouedec MC; Cambazard F; Bottigioli D; Grande S; Dahel K; Bérard F; Rabilloud M; Mercier C; Nicolas JF
J Allergy Clin Immunol Pract; 2018; 6(2):562-569.e3. PubMed ID: 28967549
[TBL] [Abstract][Full Text] [Related]
10. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
11. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
12. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Bieber T; Kleyn CE; Nosbaum A; Grond S; Petto H; Riedl E; Wollenberg A
J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
[TBL] [Abstract][Full Text] [Related]
16. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate vs. ciclosporin in the treatment of severe atopic dermatitis in children: a critical appraisal.
Tsakok T; Flohr C
Br J Dermatol; 2014 Mar; 170(3):496-8; discussion 498-9. PubMed ID: 24617431
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
19. Specific allergen immunotherapy for the treatment of atopic eczema.
Tam H; Calderon MA; Manikam L; Nankervis H; García Núñez I; Williams HC; Durham S; Boyle RJ
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008774. PubMed ID: 26871981
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
